CTMX
CytomX Therapeutics Inc
2.60$
-2.7%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Cash Flow
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -69.1% | -82.5% | -62.8% | -77.8% | -62.0% | -52.3% | -41.3% | -84.4% | -260.7% | -3,505.7% | -249.1% | -1,274.2% | -450.3% | |
| 1.8% | 1.8% | 1.1% | 1.8% | 1.3% | 1.1% | 0.8% | 1.9% | 2.2% | 76.9% | 0.4% | 5.9% | 4.2% | |
| 4.6% | 9.6% | 4.6% | 7.5% | 6.0% | 4.9% | 3.9% | 7.7% | 23.2% | 223.1% | 45.9% | 181.7% | 55.4% | |
| -83.2% | -92.4% | -99.7% | -59.4% | -85.8% | -108.8% | -93.5% | -96.9% | -55.9% | 65.5% | -123.5% | 2.6% | -84.8% | |
| 0.0% | 1.0% | 0.3% | 0.4% | 0.1% | 0.2% | 0.2% | 0.1% | 2.1% | 30.3% | 0.0% | 0.0% | 1.8% | |
| -162.7% | 48.4% | 108.3% | 85.7% | 54.3% | 39.7% | 60.1% | -409.3% | 7.4% | -2,174.8% | -1,879.3% | 419.8% | -1,097.2% | |
| – | – | – | – | – | – | – | – | – | 452.8% | – | – | – | |
| 112.5% | 0.9% | 0.4% | 20.3% | 0.0% | 5.9% | 0.0% | 501.4% | 4.2% | 2,510.3% | 2,285.9% | 36.0% | 1,376.3% | |
| -119.4% | -33.3% | 45.9% | 28.1% | -7.7% | -6.6% | 18.8% | 7.7% | -249.1% | -3,170.3% | 157.5% | -818.3% | -171.1% | |
| -69.2% | -83.5% | -63.1% | -78.2% | -62.1% | -52.5% | -41.6% | -84.6% | -258.6% | -3,536.0% | -249.1% | -1,274.2% | -450.7% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.